Capiri-sutent Phase-1 in Advanced Colo-rectal Cancer (sutent-capiri)

Radboud University Medical Center

Status and phase

Unknown

Phase 1

Conditions

Colorectal Cancer

Treatments

Drug: capiri-sutent

Study type

Interventional

Funder types

Other

Identifiers

NCT00777478

UMCNONCO20083

Details and patient eligibility

About

The primary objective of this Phase 1 study is to identify the recommended dose of capiri and of sunitinib for combination therapy subsequent phase II trials.

Enrollment

32 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histological proof of colorectal cancer
Patients should have failed one previous line of systemic treatment for advanced disease (and not more than one treatment line), either with fluoropyrimidine monotherapy or in combination with oxaliplatin and/or bevacizumab.
No prior treatment with irinotecan or sunitinib
Age ≥ 18 years
WHO PS 0-1 (see Appendix 3, corresponding with Karnofsky ≥ 70% )
Life expectancy ≥ 12 weeks
Written informed consent

Exclusion criteria

No measurable disease according to RECIST criteria.
Prior anti-cancer therapy < 3 weeks before first dose. For cetuximab < 30 days or bevacizumab < 60 days prior to the first dose.
Unresolved toxicity > CTC gr 1 from previous anti-cancer therapy (including radiotherapy) except for alopecia.
Inadequate bone marrow function (Hb ≤ 5.6 mmol/L, absolute neutrophil count (ANC) ≤ 1.5 x 109/L, platelets ≤100 x 109/L)
renal dysfunction (serum creatinine ≥ 1.5x ULN and glomerular filtration rate ≤ 50 ml/min)
Prothrombin time (PT) and activated partial thromboplastin time (APTT) > 2x ULRR
Hepatic dysfunction (serum bilirubin ≥ 1.5x ULN, serum transaminases ≥ 2.5 x ULN)
Greater than +1 proteinuria on two consecutive dipsticks taken no less then 2 weeks apart unless urinary protein < 1,5 g in a 24 Hr period.
Pregnant or lactating women
History of clinical signs/symptoms of CNS metastases
Previous intolerance of fluoropyrimidine therapy, known dihydropyrimidine dehydrogenase (DPD) deficiency. Known hypersensitivity to irinotecan or sunitinib of their excipients.
No major surgery < 4 weeks prior to study entry.
No radiotherapy < 4 weeks prior to study entry except for palliative radiotherapy at focal sites.
Any evidence of concurrent severe or uncontrolled disease (i.e. uncontrolled hypertension, congestive heart failure, myocardial infarction < 6 months, chronic active infection, poorly regulated diabetes mellitus)
Any previous significant cardiovascular event during previous fluoropyrimidine therapy (i.e.

myocardial ischemia or infarction, arterial thrombosis, pulmonary emboli)

Mean Qtc with Bazetts correction > 470 msec in screening ECG, or a history with familial long QT syndrome
Significant haemorrhage (>30 ml bleeding/episode in the last 3 months) or haemoptysis (>5 ml fresh blood in previous 4 weeks)
History of impairment of gastrointestinal function or -disease that may significantly impair the absorption of oral drugs (i.e. uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome, bowel obstruction, or inability to swallow tablets)
Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
Concomitant use medication that may significantly affect hepatic cytochrome P450 drug metabolizing activity by way of enzyme induction or inhibition < 2 weeks if the first dose and throughout the study period (see Appendix 2)
Other concomitant anti-cancer therapy.